Gemcitabine
Gemzar · Nucleoside analog
Dose-cumulative thrombotic microangiopathy.
TMAHTNGLOM
SevereOpen →
Alkylator
Busulfan
Myleran · Bu
A conditioning alkylator that can injure the transplant endothelium and trigger microangiopathy.
ModerateAlkylator · approved 1954
Hematopoietic stem cell transplant conditioningChronic myeloid leukemia (historical)
Signature kidney injury
Thrombotic Microangiopathy
Transplant-associated thrombotic microangiopathy (TA-TMA) with renal involvement complicates a subset of conditioning regimens; high-dose busulfan (e.g., 16 mg/kg) has been identified as an independent risk factor for post-transplant TMA, and high busulfan exposure also drives sinusoidal obstruction syndrome/VOD.
Source: Nakamae et al., Am J Hematol 2006
Mechanism of kidney injury
Conditioning-related endothelial injury - amplified by high busulfan AUC, calcineurin inhibitors, GVHD, infection and complement dysregulation - drives a thrombotic microangiopathy with platelet/fibrin microthrombi in the renal microvasculature, microangiopathic hemolysis and renal ischemia. The same endothelial toxicity at high exposure produces hepatic sinusoidal obstruction syndrome (VOD), which can cause hepatorenal-type renal hypoperfusion. TA-TMA is multifactorial; busulfan intensity is one contributing factor.
Clinical presentation
Microangiopathic hemolytic anemia (schistocytes, elevated LDH, low haptoglobin), thrombocytopenia, hypertension, proteinuria and rising creatinine after transplant; if VOD coexists, weight gain, hepatomegaly and hyperbilirubinemia with secondary renal hypoperfusion.
Onset
Weeks after conditioning/transplant.
Reversibility
Variable
Anticancer mechanism
Bifunctional alkylsulfonate that cross-links DNA, intensely myelosuppressive with a narrow therapeutic window. Used historically for chronic myeloid leukemia and, principally, as a high-dose conditioning agent (with cyclophosphamide or fludarabine) before hematopoietic stem cell transplant.
Management
Identify and treat triggers (reduce/adjust calcineurin inhibitor, treat GVHD/infection), supportive care, and consider complement-directed therapy (eculizumab) in severe TA-TMA. Renal outcomes range from recovery to chronic kidney disease.
Risk factors
- High-dose / high-AUC busulfan conditioning
- Calcineurin inhibitors (tacrolimus/cyclosporine)
- Acute graft-versus-host disease
- Concurrent infection / total body irradiation / sinusoidal obstruction syndrome
Prevention
- Therapeutic busulfan dosing with PK/AUC level monitoring to limit excess exposure
- Screening for TA-TMA (schistocytes, LDH, haptoglobin, urinalysis) during and after transplant
- Minimize additive endothelial insults where possible
Note · TA-TMA is regimen- and context-dependent rather than a pure single-drug effect; busulfan is one contributing factor among several, and PK-guided dosing is the main modifiable lever.
Clinical depth
Renal dose adjustment
Busulfan clearance is largely hepatic (GST-mediated); no formal renal CrCl dose banding, but AUC-targeted (therapeutic-drug-monitoring) dosing is standard to avoid the high exposures linked to TMA and VOD. Reduced clearance at high doses warrants level monitoring.
Dialyzability & ESKD dosing
Busulfan is moderately dialyzable in principle, but TDM-guided dosing (not dialysis) is the control strategy; dialysis is reserved for managing TA-TMA-related renal failure rather than for drug removal.
Differential diagnosis
TA-TMA (schistocytes, elevated LDH, low haptoglobin, thrombocytopenia, hypertension, proteinuria) vs calcineurin-inhibitor nephrotoxicity (often without hemolysis), vs VOD-related hepatorenal hypoperfusion (weight gain, hyperbilirubinemia), vs sepsis/ATN. ADAMTS13 is typically not severely deficient, distinguishing TA-TMA from TTP.
Monitoring
- Busulfan plasma levels/AUC (therapeutic drug monitoring) during conditioning
- Schistocytes, LDH, haptoglobin, platelets and creatinine post-transplant (TA-TMA panel)
- Bilirubin/weight/liver exam for sinusoidal obstruction syndrome
Key trials & series
- Ho BMT-CTN consensus Biol Blood Marrow Transplant 2005 - defines post-transplant TMA including the renal component
- Nakamae Am J Hematol 2006 - high-dose busulfan as an independent TA-TMA risk factor
- Tolbert Biol Blood Marrow Transplant 2019 - conditioning regimen as key determinant of TA-TMA with renal injury
Clinical pearls
- PK-guided (AUC-targeted) busulfan dosing is the single best lever to reduce both TA-TMA and VOD risk.
- TA-TMA is a complement-mediated, multifactorial endothelial injury - busulfan is a contributor, not the sole cause.
- Look for the haptoglobin/LDH/schistocyte triad with rising creatinine weeks post-transplant before anchoring on calcineurin-inhibitor toxicity.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Thrombotic Microangiopathy
Beyond the kidney
Class-level context for the major non-renal toxicities of alkylators.
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression; secondary malignancy risk
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Ifosfamide encephalopathy (chloroacetaldehyde)
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- High-dose cyclophosphamide cardiotoxicity
Evidence
8 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkBlood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.Ho VT et al. · Biol Blood Marrow Transplant 2005 · PMID 16041306Foundational consensus defining post-transplant TMA, including its renal-failure component.PMIDRisk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.Nakamae H et al. · Am J Hematol 2006 · PMID 16755559High-dose busulfan identified as an independent risk factor for post-transplant TMA.PMIDRisk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.Tolbert VP et al. · Biol Blood Marrow Transplant 2019 · PMID 31199983Conditioning regimen as the key determinant of TA-TMA with renal injury.PMIDPhase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.O'Donnell PH et al. · Leuk Lymphoma 2010 · PMID 20919852Busulfan AUC-SOS/VOD dose-response and the rationale for PK monitoring.PMIDGSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.Ansari M et al. · Oncotarget 2017 · PMID 29207608Busulfan clearance pharmacogenetics and conditioning toxicity, supporting TDM.PMIDDiagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?Batts ED et al. · Bone Marrow Transplant 2007 · PMID 17603513TA-TMA pathophysiology and management review in the conditioning setting.PMIDThrombosis in stem cell transplantation.Kansu E · Hematology 2012 · PMID 22507809Covers busulfan-related SOS/VOD and TA-TMA with renal failure.PMIDAnticancer drug-induced kidney disorders.Kintzel PE · Drug Saf 2001 · PMID 11219485Onconephrology context for chemotherapy-associated microvascular renal injury.